Investment group Atlas Ventures has closed its fourteenth fund, raising $450 million for the next round of investment in biotech start-ups. Fund XIV comes two years after Atlas' last fund and will ...

The outlook for drug development to treat rare diseases looks encouraging, offering hope to the 300 million people globally facing the significant challenges of these often-overlooked conditions.

In a new report, ‘Proactive Planning to Navigate Clinical Research Staffing Trends in 2025’, Advanced Clinical looks at hiring trends in 2024, providing valuable insights for navigating ...

Looking ahead, the momentum gained in 2024 must be maintained and amplified. By fostering a culture of belonging in the ...

My conclusion, having worked in various regions and corporate settings: don’t be loud. Be yourself. Be decent. Be ...

The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...

The Pharmaceutical Research and Manufacturers of America (PhRMA) trade body is donating $1 million to fund President-elect ...

Embedded heuristics and decision-making: In pharma, many decisions are guided by both data and heuristics (i.e., rules of ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Healthcare professionals (HCPs) rely on biopharma companies for accurate drug information. Out-of-date claims can damage both brand reputation and industry credibility. This puts pressure on ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.